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Background: Candida albicans infections have become increasingly recognised as being biofilm related. Recent
studies have shown that there is a relationship between biofilm formation and poor clinical outcomes in patients
infected with biofilm proficient strains. Here we have investigated a panel of clinical isolates in an attempt to
evaluate their phenotypic and transcriptional properties in an attempt to differentiate and define levels of biofilm
formation.
Results: Biofilm formation was shown to be heterogeneous; with isolates being defined as either high or low
biofilm formers (LBF and HBF) based on different biomass quantification. These categories could also be differentiated
using a cell surface hydrophobicity assay with 24 h biofilms. HBF isolates were more resistance to amphotericin B (AMB)
treatment than LBF, but not voriconazole (VRZ). In a Galleria mellonella model of infection HBF mortality was significantly
increased in comparison to LBF. Histological analysis of the HBF showed hyphal elements intertwined indicative of the
biofilm phenotype. Transcriptional analysis of 23 genes implicated in biofilm formation showed no significant differential
expression profiles between LBF and HBF, except for Cdr1 at 4 and 24 h. Cluster analysis showed similar patterns
of expression for different functional classes of genes, though correlation analysis of the 4 h biofilms with overall
biomass at 24 h showed that 7 genes were correlated with high levels of biofilm, including Als3, Eap1, Cph1,
Sap5, Plb1, Cdr1 and Zap1.
Conclusions: Our findings show that biofilm formation is variable amongst C. albicans isolates, and categorising
isolates depending on this can be used to predict how pathogenic the isolate will behave clinically. We have
shown that looking at individual genes in less informative than looking at multiple genes when trying to categorise
isolates at LBF or HBF. These findings are important when developing biofilm-specific diagnostics as these could be used
to predict how best to treat patients infected with C. albicans. Further studies are required to evaluate this clinically.
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Bloodstream infections (BSI) caused by Candida species
remain a frequent cause of morbidity and mortality,
particularly within the immunocompromised population
[1,2]. Overall, Candida species have been identified as the
most common fungal pathogen found in bloodstream in-
fections in the United States, and are the fourth most com-
mon organism responsible for all BSI, and are the third
most common within the intensive care unit (ICU) [2].
Candidaemia is often associated with the ability of Candida
to adhere to and form biofilms on indwelling medical
devices, such as central venous catheters (CVC) and pros-
thesis [3,4]. Biofilms are a population of microorganisms
attached to one another and/or a surface, surrounded by an
extracellular matrix (ECM) [5].
A defining feature of biofilms is their resistance to
antimicrobial therapy, with higher drug concentrations
required to kill biofilms and their dispersed cells when
compared to equivalent free-floating planktonic cells
[5-7]. Another feature of C. albicans biofilms is their en-
hanced pathogenicity. For example, cells detaching from
biofilms have been shown to be more cytotoxic than
their planktonic counterparts and significantly increase
mortality within a murine model of infection [7]. These
observations have been demonstrated clinically, where a
significant association was observed between C. albicans
biofilm formation and mortality rates in candidaemia pa-
tients [8].
Whilst there is growing evidence of the importance of
Candida biofilms in clinical medicine, not all clinical
isolates are able to form biofilms. There is therefore a
fundamental gap in understanding exactly what drives
biofilm formation and its clinical implications. Establish-
ing methods to differentiate these isolates is challenging,
as many studies rely on either metabolic assays or biomass,
and these frequently use a variety of different substrates
and media [9-12]. Therefore, comparison between these
studies is not possible, and further interpretation of the data
to improve clinical management both for diagnostics and
antifungal therapy is limited. The purpose of this study was
therefore to investigate and characterise biofilm formation
by clinical isolates of C. albicans using standard methodolo-
gies and subsequently analyse biofilm subsets phenotypic-
ally and transcriptionally. Here we report that C. albicans
clinical isolates form biofilms that are heterogeneous, and
this is associated with altered antifungal drug sensitivity
and pathogenic potential.
Results
Candida albicans clinical isolates exhibit heterogeneous
biofilm formation
C. albicans bloodstream isolates displayed heterogeneity
with respect to their biofilm biomass when grown in
RPMI (Figure 1A). RPMI was shown to support theoptimal growth of C. albicans over 24, 48 and 72 h
(Additional file 1: Figure S1). Isolates were categorised as
low biofilm formers (LBF) or high biofilm formers (HBF)
if their biomass absorbance were less than the first quartile
(Q1 OD570 = 0.565) or greater than the third quartile (Q3
OD570 = 1.682), respectively. Those isolates in between the
first and third quartile (Q1-Q3) were defined as intermedi-
ate biofilm formers. When HBF were stained with crystal
violet (cv), the extent of the biofilm formation was observed
macroscopically, where the bottom of the well was clearly
covered with cellular biomass (Figure 1A). In contrast, min-
imal staining was retained on isolates classed as LBF, as
demonstrated by the well remaining almost colourless. We
analysed a subset of isolates from the LBF and HBF group
(n = 3) using dry weight measurements and confirmed our
previous observations that biofilm biomass was significantly
greater in isolates termed HBF (p = 0.0023) (Figure 1B).
These differences are clearly evident when viewed under a
SEM at low (Figure 1C [i, iii]) and high magnification
(Figure 1C [ii, iv]). LBF isolates were characterised by a
predominance of yeast cells and lack of hyphal cells
(Figure 1C i, ii). In contrast, C. albicans HBF were
highly filamentous with a multi-dimensional structure
with very few yeast cells (Figure 1C iii, iv).
Biofilm phenotype is affected by cell surface hydrophobicity
(CSH)
The CSH of LBF and HBF isolates was quantified to deter-
mine whether it played a role in biofilm forming ability
[13]. Figure 2 illustrates that the hydrophobicity of an iso-
late significantly alters its ability to form a biofilm. For LBF
the CSH increased by 32% and 31% in 4 h (p < 0.05) and
24 h (p < 0.0005) biofilms, respectively, when compared to
planktonic cells. This trend was also observed in isolates
with HBF where CSH increased by 50% in 4 h (p < 0.0001)
biofilms and 81% in 24 h (p < 0.0001) biofilms, when com-
pared with planktonic counterparts. Furthermore, a signifi-
cant increase in CSH was found in isolates with HBF
between early (4 h) and mature (24 h) phases of biofilm
development, where hydrophobicity increased by 31% (p <
0.001). When the hydrophobicity of LBF and HBF was
compared, CSH was significantly increased by 41% in HBF
isolates at 24 h (p < 0.0001); however, no significant differ-
ence was observed between isolates with LBF and HBF in
planktonic cells and 4 h biofilms.
Amphotericin B activity is impacted by biofilm phenotype
Sessile antifungal testing was performed on C. albicans
isolates with LBF and HBF to determine if one group
were more susceptible to VRZ or AMB treatment. VRZ
was ineffective against all biofilms tested, showing no
difference in activity against LBF and HBF (data not
shown). However, a dose-dependent effect was evident
in all isolates tested with AMB (Figure 3). Moreover, a
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Figure 1 Candida albicans clinical isolates vary in their ability to form biofilms. Forty-two C. albicans bloodstream isolates were used to
evaluate biofilm formation of strains derived from a clinical setting. (A) Standardised C. albicans (1 × 106 cells/mL) in RPMI-1640 were grown in
flat-bottomed 96 well microtitre plates for 24 h at 37°C. Mature biofilms were carefully washed with PBS, allowed to air dry and biomass quantified by
staining with 0.05% w/v crystal violet solution. The biofilms were washed and destained with 100% ethanol. Biomass was quantified spectrophotometrically
by reading absorbance at 570 nm in a microtitre plate reader (FluoStar Omega, BMG Labtech). Eight replicates were used for each isolate and was carried
out on two separate occasions, with the mean of each represented. C. albicans LBF (square), HBF (triangle) and IBF (circle) were defined by the upper and
lower quartiles, as shown by crystal violet stained biofilms. (B) Three C. albicans LBF and HBF were standardised (1 × 106 cells/mL) in RPMI-1640 and grown
in 12 well plates for 24 h at 37°C. Biofilms were washed with PBS, biomass scraped and passed through 0.22 μm filters before the filters containing the
biofilms were dried at 37°C for 24 h. Biofilm dry weight was then measured for LBF and HBF, in triplicate on three separate occasions. Data represents
mean ± SD with significance **p < 0.005. (C) One C. albicans LBF (i, ii) and HBF (iii, iv) were grown on Thermanox™ coverslips for 24 h at 37°C. Biofilms
were then processed and viewed on a JEOL JSM-6400 scanning electron microscope and images assembled using Photoshop software. Note the lack of
biomass and hyphal cells in LBF. Scale bars represent 20 μm and 5 μm for 1000× (i, iii) and 3000× (ii, iv) magnifications, respectively.
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HBF treated with 0.25 – 32 mg/L AMB (p < 0.05). LBF
and HBF isolates both had a MIC50 of 0.25 mg/L AMB,
yet isolates with LBF were significantly less viable than
those with HBF at this concentration (p = 0.0307). In
addition, LBF isolates achieved an ~80% kill at 4 mg/L,
whereas HBF required 32 mg/L to reach the same kill.
No significant differences were observed in the growth
rates of either set of LBF and HBF isolates (data not
shown).
In vivo pathogenicity is affected by biofilm phenotype
We next analysed the impact of the isolates ability to
form biofilms based upon the severity of infection using
a previously described G. mellonella model. The average
rate of killing by three HBF, three LBF and a reference
strain (SC5314) of C. albicans were calculated to plot a
survival curve. Survival data showed a significant difference
in the killing of larvae between HBF and LBF (p < 0.0001
[Figure 4A]). After 2 and 6 days, respectively, >50% and100% larval death was recorded for HBF isolates, whereas
larvae infected with LBF only achieved 20% killing after
7 days challenge. The reference strain SC5314 achieved
50% and 100% larval death by day 4 and 7, respectively.
Similar kill rates to that of HBF were observed in the type
strain however, when compared to LBF there was a signifi-
cant difference in larval mortality (p = 0.0005).
Host-pathogen interactions in this model were then
investigated by microscopically observing the morph-
ology of the infected larvae at 24, 48 and 72 h post-
infection with C. albicans HBF and LBF (Figure 4B). At
24 h in both the LBF (Figure 4Bi) and HBF (Figure 4Biv),
the nodule formation and melanin deposition were
mainly observed under the cuticle and in the fat body,
with mild to strong melanisation observed in the centre
of the nodules, together with the presence of yeast cells
and/or hyphae. The LBF nodules were smaller in dimension
and dispersed mainly in the subcuticle area (Figure 4Bi),
whereas the HBF nodules had a stronger melanisation with
the tendency to converge in large aggregates, and were
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Figure 2 Cell surface hydrophobicity impacts biofilm
phenotype. Ten C. albicans LBF and HBF were standardised (1 × 106
cells/mL) in RPMI-1640 and grown in 75 cm2 flasks for 4 and 24 h.
Biofilms were washed with PBS, biomass scraped in to YPD media
and standardised to OD590nm 1.0 before xylene was added to each
sample. Planktonic cells were also standardised to OD590nm 1.0.
Samples were allowed to separate into two phases and the OD590nm
of the lower aqueous layer was measured (i). A visual representation
hydrophobicity is shown for planktonic LBF (ii) and HBF (iii), 4 h
biofilms LBF (iv) and HBF (v) and 24 h biofilms LBF (vi) and HBF (vii).
Note the cloudy upper layer denoted by arrows showing hydrophobic
cells. Ten isolates from each group were measured on two separate
occasions. Data represented mean ± SD. Significant differences between
LBF and HBF were observed when 4 and 24 h biofilms were compared
to their planktonic counterparts (*p < 0.05, ***p < 0.0001, ###p < 0.0001).
Furthermore, significant differences were found between 4 and 24 h in
HBF (†††p < 0.0001) and between LBF and HBF at 24 h (§§§p < 0.0001).
Figure 3 Amphotericin B sensitivity is significantly impacted by biofil
1 × 106 cells/mL in RPMI-1640 and grown as biofilms in flat-bottomed 96 w
treated with 2 fold serial dilutions of amphotericin B for 24 h. Biofilms were
assay with absorbance read at 492 nm. Each isolate was tested in duplicate
*p < 0.05, **p < 0.01, ***p < 0.001.
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48 h, the LBF were confined to the external part of the vis-
ceral organs, with a spot-like distribution (Figure 4Bii);
whereas the HBF were found to display a pronounced fila-
mentation all around the intestinal wall, with a PAS positive
matrix visible surrounding the hyphae (Figure 4Bv). Fur-
thermore at 72 h, there was a substantial invasion of both
the gastrointestinal tract and the tracheal system with dam-
aged gut epithelium, where yeast and hyphal cells both ob-
served in the HBF infection (Figure 4Bvi). In contrast, a
segmental invasion of the intestinal wall (Figure 4Biii) was
observed with LBF infection and the progression of the in-
fection was to a lesser extent than that by the HBF. Table 1
summarises the localisation and characterisation of the
nodules with LBF and HBF infected larvae. Changes in the
fat body morphology and composition including vacuolisa-
tion and haemocyte recruitment, were detected during the
course of the infection and were more evident in the HBF.
Transcriptional heterogeneity is associated with biofilm
phenotype
C. albicans clinical isolates defined as LBF and HBF were
further assessed at a transcriptional level and the expression
of genes related to biofilm formation was investigated.
ACT1 was used as the housekeeping gene and was shown
to be stably expressed throughout all biofilm conditions.
Figure 5 illustrates the levels of gene expression of LBF
(n = 10) versus HBF (n = 10) at both (A) 4 and (B) 24 h.
Overall, the majority of the genes tested followed a trend
of up-regulation in HBF compared to LBF. However,m formation. Ten isolates with LBF and HBF were standardised to
ell microtitre plates for 24 h. Biofilms were washed with PBS before
washed and metabolic activity measured using the XTT metabolic
, on three separate occasions with data represented by mean ± SEM.
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Figure 4 C. albicans HBF have a significant impact on morbidity and mortality rate in vivo. Larvae of G. mellonella were infected with C.
albicans LBF or HBF at 1 × 105 CFU/larva and monitored over a period of 7 days (A). Kaplan-Meier plots of G. mellonella survival after injection of
C. albicans demonstrated a strain dependant variation in pathogenicity in vivo. Groups of HBF and LBF clinical isolates were compared to each
other and to the SC5314 type strain. The HBF isolates resulted in higher killing rate compared to LBF and SC5314. In contrast, LBF isolates exhibit
a slower rate of kill and 100% mortality did not occur within 7 days. PBS injected larvae were included as a negative control. (B) Infected larvae
were formalin fixed and sectioned for histology analysis. At 24 h, LBF infected larvae (i) had several melanisation spots and nodules were present
mainly under the cuticle and in the peripheral fat body (Feulgen staining, 20× original magnification (o.m.); inset: 4× o.m.), whereas HBF infected
larvae (iv) had larger nodules with a greater melanin deposition characterised by the recruitment in the external layers of a huge number of
haemocytes (20× o.m.; inset: 10× o.m). At 48 h, LBF (ii) small nodules containing both yeast and some hyphae were observed deeper in the
larval tissues, sometimes reaching the external part of the gut wall (PAS staining, 20× o.m.; inset: 10× o.m), with HBF (v) having elongated hyphae
targeting the intestinal walls (PAS staining, 40× o.m.; inset: 10× o.m.) At 72 h, LBF (iii) showed segmental invasion of the gut walls (PAS staining,
20× o.m.; inset: 10× o.m.) however, HBF (vi) displayed hyphae endoluminal invasion after breaching the intestinal wall (PAS staining, 40× o.m.;
inset: 10× o.m.) with few yeast cells.
Table 1 Characteristics and localisation of nodules found in infected G. mellonella larvae
Nodules
Size Melanisation Encapsulation Confluence Fungal morphology Localisation
Yeast cells Hyphae SC FB PI PT
LBF Small + + - +++ +* + + ++ -
HBF Large ++, +++ +++ + + +++** ++ ++ +++ +
SC: subcuticle, FB: fat body, PI: paraintestinal, PT: paratracheal.
*short squat hyphae, **long tangled hyphae often embedded in an extracellular matrix.
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Figure 5 Genes associated with C. albicans biofilm development are up-regulated in HBF. Ten C. albicans isolates with LBF and HBF were
standardised to 1 × 106 cells/mL in RPMI-1640 and grown as biofilms in 24 well microtitre plates for 4 (A) and 24 h (B) at 37°C. Biofilms were
washed with PBS and RNA extracted using the TRIzol method, cDNA synthesised and real-time PCR used to measure the expression of genes
related to C. albicans biofilm formation. Percentage of gene expression is shown as log10 mean ± SD, relative to housekeeping gene ACT1. All strains were
assessed in duplicate and included appropriate no RT and non-template controls. *p < 0.05, **p < 0.005.
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http://www.biomedcentral.com/1471-2180/14/182statistically significant differences were observed in the gly-
cosylated mannoproteins MNN4 (p = 0.0313) and MNT2
(p = 0.0044) at 4 h, where expression was increased by
~2 fold. Furthermore, the resistance gene CDR1 was
significantly increased in HBF by 4- and 6-fold at 4 h
(p = 0.0113) and 24 h (p = 0.0239), respectively (Additional
file 2: Table S1).
Clustering the expression of 23 selected genes from 5
different functional groups in a heat map showed their
relationship with one another and their variable expres-
sion in LBF and HBF over time (Figure 6). Here we
found the adhesion genes ALS3 and HWP1 were closely
related and highly expressed, particularly in HBF isolates
at 4 and 24 h. Furthermore, genes from different functio-
nal groups were closely related to one another irrespective
of whether LBF or HBF, such as the proteinase SAP5 and
the adhesion genes ALS5 and EAP1. The remaining SAP
genes were all closely related to one another, and inte-
restingly the resistance gene MDR1 and the cell wall man-
noprotein OCH1. Further analysis of SAP3 showed an
increase in transcription within LBF at 24 h, despite no
differences being observed at 4 h. In contrast, SAP5 ex-
pression was consistently high at 4 and 24 h within HBF.
Analysis of Spearman rho coefficients found that out
of 23 selected genes, 7 including those related to adhe-
sion (ALS3, EAP1), filamentation (CPH1), hydrolytic en-
zymes (SAP5, PLB1) and resistance (CDR1 and ZAP1)
showed a significant positive correlation (p < 0.05) with
cv biomass data at 4 h (Table 2). Further analysis of the
relationship between these seven genes and all the other
genes tested presented various correlations (marked bold
in Table 2). For example, PLB1 was significantly corre-
lated with all other genes tested (94.11%) except ZAP1,followed by CPH1 (76.47%), SAP5 (76.47%), EAP1
(64.71%), CDR1 (41.17%), ALS3 (35.29%) and ZAP1
(11.76%). Correlation of individual genes with one an-
other at the 4 h time point showed that PLB1, CPH1,
MNN4 and HWP1 all correlated with 5 of the 7 key genes
defined above. Notably, 24 h gene expression revealed very
few significant correlations other than cv. In fact, a signi-
ficant negative correlation was found between SAP3 and
the biomass data (Rho = −0.465, p = 0.045). Furthermore,
SAP3 was positively correlated with MNT2 (Rho = 0.468,
p = 0.043) and SAP4 (Rho = 0.460, p = 0.048).
Discussion
C. albicans is an important pathogen. It is the fourth
most common organism isolated from total bloodstream
infections [2] and continues to carry a high mortality.
The presence of medical devices such as central venous
catheters (CVC’s) are known to be important risk factors
[14] suggesting that biofilm formation is a key feature in
the pathogenesis of candidaemia. The past decade has
seen a significant leap in our knowledge and understand-
ing of the biology of C. albicans biofilms, particularly with
respect to the molecular basis of their development and
homeostasis [15]. However, in the clinical setting it is gener-
ally assumed that all C. albicans isolates have the capacity
to form biofilms, but often with little regard to individual
differences within the species when managing the infection.
Here we demonstrate that C. albicans display heteroge-
neous biofilm characteristics, and these strain differences
have important implications with respect to treatment and
pathogenicity.
Previous studies have reported very defined categories in
their analysis of association with clinical outcomes, i.e.
Figure 6 Clustering analysis identified the transcriptional relationship of biofilm specific genes. Percentage expression of each gene was
also assessed by clustering and heat map analysis using GenEx software. Data was log transformed and mean values were used for heat map
construction. Increased expression of genes is shown by red and a decrease is represented by green.
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these important studies fail to take into account the hetero-
geneous nature of individual clinical isolates forming bio-
films, which based on their metabolic XTT values can
range from 0.125 to 1.358 [16]. When looking for clinical
correlations with these phenotypes then important infor-
mation can be missed, as the isolates at either end of thebiofilm forming spectrum may lead to different clinical out-
comes. We therefore aimed to evaluate and categorise C.
albicans biofilms into distinct levels of biofilm formation to
determine if their biological features were significantly dif-
ferent. Initially we categorised biofilms grown in RPMI
using a biomass stain [17] and followed this up with dry
weight analysis, which differentiated clinical isolates into
Table 2 C albicans biomass correlates with biofilm-related gene expression
4 h Correlationsa ALS3 EAP1 CPH1 SAP5 PLB1 CDR1 ZAP1
CV Rho= .529* .608** .534* .539* .483* .647** .515*
p = .029 .010 .027 .026 .050 .005 .035
ALS1 Rho= .240 .529* .542* .336 .608** .382 .250
p = .353 .029 .025 .188 .010 .130 .333
ALS3 Rho= 1.000 .385 .708** .544* .593* .779** .365
p = .127 .001 .024 .012 .000 .149
ALS5 Rho= .229 .538* .644** .607** .681** .145 .214
p = .378 .026 .005 .010 .003 .579 .410
EAP1 Rho= .385 1.000 .544* .490* .860** .537* .279
p = .127 .024 .046 .000 .026 .277
HWP1 Rho= .868** .338 .821** .571* .532* .615** .201
p = .000 .184 .000 .017 .028 .009 .439
MNN4 Rho= .350 .554* .645** .537* .672** .493* .309
p = .168 .021 .005 .026 .003 .045 .228
PMR1 Rho= .333 .635** .527* .534* .784** .233 .377
p = .191 .006 .030 .027 .000 .368 .135
BCR1 Rho= .262 .250 .539* .566* .485* .306 .522*
p = .309 .333 .026 .018 .048 .232 .032
CPH1 Rho= .708** .544* 1.000 .833** .748** .547* .321
p = .001 .024 .000 .001 .023 .209
EFG1 Rho= .257 .520* .576* .645** .605* .409 .392
p = .319 .033 .016 .005 .010 .103 .119
TUP1 Rho= .713** .397 .397 .463 .544* .684** .444
p = .001 .115 .115 .061 .024 .002 .074
SAP1 Rho= .356 .523* .794** .744** .730** .251 .413
p = .160 .031 .000 .001 .001 .332 .100
SAP2 Rho= .091 .554* .478 .417 .654** .172 .292
p = .729 .021 .052 .096 .004 .510 .256
SAP5 Rho= .544* .490* .833** 1.000 .676** .395 .539*
p = .024 .046 .000 .003 .117 .026
SAP6 Rho= .371 .772** .637** .627** .869** .320 .284
p = .143 .000 .006 .007 .000 .211 .269
PLB1 Rho= .593* .860** .748** .676** 1.000 .532* .434
p = .012 .000 .001 .003 .028 .082
CDR1 Rho= .779** .537* .547* .395 .532* 1.000 .262
p = .000 .026 .023 .117 .028 .309
ZAP1 Rho= .365 .279 .321 .539* .434 .262 1.000
p = .149 .277 .209 .026 .082 .309
*Correlation is significant at the 0.05 level (2-tailed), ** Correlation is significant at the 0.01 level (2-tailed).
a. List wise N = 17.
Sherry et al. BMC Microbiology 2014, 14:182 Page 8 of 14
http://www.biomedcentral.com/1471-2180/14/182defined groupings. This approach was used in preference to
metabolic assays due to the highly variable nature of XTT
from strain to strain [16]. Moreover, XTT’s mainstay useful-
ness is limited to antifungal drug testing of biofilms [11,18].
Our classification, based initially on biomass, was supportedby observations on a macro- and microscopic level where it
was clear that numerous cells consisting of hyphae and
yeasts were visible in HBF, whereas scant layers of yeast
cells were observed for LBF. We also investigated CSH as
an additional biofilm positive feature, as previous studies
Sherry et al. BMC Microbiology 2014, 14:182 Page 9 of 14
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[13,19]. This study confirms that CSH impacts different
phases of biofilm development, which is in agreement with
previous work where it was shown that cells dispersed from
mature biofilms were more hydrophobic than those dis-
persed from earlier stages of biofilm development [20]. Fur-
thermore, it has been shown hydrophobic cells are more
adherent [21], and therefore it is unsurprising that CSH
was increased in HBF isolates. Based on our overall ap-
proach to biofilm categorisation we can be confident in the
phenotypes selected for further detailed analysis. We do
however concede there are caveats to defining levels of
biofilm, and this requires further work and collaboration
between groups to establish a standardised method.
One of the key defining features of C. albicans bio-
films is their insensitivity to sterol active antifungal
agents [5]. We examined azole treatment, which unsur-
prisingly demonstrated poor activity overall with no
group differences, presumably through adaptive resist-
ance mechanisms as previously described [22-24]. Not-
ably, AMB was less effective against HBF biofilms than
LBF, which we hypothesise is due to the inability of the
compound to permeate easily throughout the dense
physical structure of the cells encased within ECM [25].
We purposely excluded echinocandins from this study
as these have been shown to be an effective anti-biofilm
antifungals, therefore quantifying differences in activity
against the two populations would be difficult [26].
These observations may have implications to whether a
patient responds to antifungal therapy, as Tumbarello
and colleagues (2012) demonstrated that inadequate
antifungal therapy (azoles) and the presence of an in-
dwelling venous catheter were key predictors of patient
mortality and hospital length of stay in patients infected
with biofilm forming isolates [8]. Guidelines have also
suggested that removal of the catheter is an important
factor in improving clinical outcomes, again supporting
the notion that biofilm formation has a crucial role in
clinical outcomes [27,28]. Given the importance of these
infections, efficient and appropriate treatment in candi-
daemia cases has been highlighted [29,30], as failure to
treat quickly and effectively has profound consequences
on mortality statistics [31].
We decided to test the hypothesis that clinical isolates
capable of forming robust biofilms were more patho-
genic, which may be a reason for their apparent role in
infections with increased mortality [16]. Previous experi-
mental work has shown that cells dispersed from bio-
films are more cytotoxic and kill mice quicker than the
equivalent planktonic cells [7]. Using a G. mellonella
model we showed that HBF isolates caused significantly
greater mortality rates than LBF isolates, a finding sup-
ported elsewhere [32]. In addition, another study investi-
gated the virulence of C. albicans isolates with varyinglevels of biofilm formation and found that mice infected
with a LBF had increased survival rates compared to
isolates that were infected with HBF [33]. Histological ana-
lysis of the infected larvae displayed similar cell morphology
of yeast and filamentous hyphae as observed in SEM im-
ages of LBF and HBF, respectively. This is in agreement
with a previous study that showed filamentation plays a role
in killing G. mellonella larvae [34].
Filamentous growth is a characteristic feature of C.
albicans biofilm formation. Defective hyphal formation
through deletion of EFG1 has been shown to lead to
low levels of biofilm growth [35]. Given our growing
knowledge of key biofilm related genes we decided to in-
vestigate transcriptional changes to determine whether
these are truly represented amongst clinical isolates, and
therefore could be used as a more robust way to categor-
ise biofilm formation and as potential diagnostic targets
of HBF isolates. ACT1, the stably expressed housekeep-
ing gene, as reported elsewhere [36-38], enabled these
relative comparisons. Regulation of biofilm related genes
were shown to influence an isolates biomass within clin-
ical isolates, echoing work carried out by other groups
[39,40]. Cluster analysis of the selected biofilm related
genes showed a good association with functional classes
of genes, such as adhesins and proteinases, suggesting
that both LBF and HBF had conserved pathways in the
basic developmental phases of biofilm growth. However,
individual gene expression profiles were inconclusive,
showing very few clear independent significant differ-
ences, though gene expression proved interesting at 4 h.
We investigated the overall biomass at 24 h and exam-
ined how 4 h gene expression related to this. Overall
HWP1 was the most highly regulated at this time point
in both LBF and HBF, as has been shown elsewhere [39],
though no significant differences between the popula-
tions were observed. Seven other genes were however
shown to have significant positive correlations with bio-
mass. The most significant was CDR1, which was unsur-
prising as it has been shown to be transiently expressed
in different biofilm studies, though does not correspond
directly to antifungal resistance [41,42]. PLB1 was showed
to be significantly correlated with another 16 genes includ-
ing biomass, though expression appeared constitutively low
level within the biofilm, which is agreement with previous
studies [39], and may have an accessory role in the degrad-
ation of host tissue alongside SAP’s. Of these, SAP5 was
shown to be highly expressed in mature biofilms, and
correlated with biomass and 13 other genes. We previously
reported that SAP5 was associated with higher levels of ex-
pression in in vitro biofilms formed from denture stomatitis
C. albicans isolates [43]. In addition, Nailis and colleagues
demonstrated its crucial role both in a reconstituted human
epithelial model and within in vivo biofilms [39]. Further-
more, the role of Sap5 in biofilm formation has recently
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cantly increased when compared to planktonic counter-
parts [44]. Adhesins, such as ALS3 was also upregulated,
which has previously been identified to be involved in bio-
film formation, particularly at early stages of biofilm devel-
opment (0–6 h) [45,46], where C. albicans mutants lacking
this gene produce sparse biofilms on catheter material
in vitro [47]. EAP1, though showing no clear independent
association with biofilm formation per se, did show a clear
correlation with biomass and 11 other genes. Its import-
ance in biofilm formation has been reported previously
[48]. Of interest was the positive correlation with ZAP1 ex-
pression at 4 h, which is a negative regulator of matrix pro-
duction [49]. It did positively correlate with BCR1, the
global regulator of biofilm formation, suggesting that the
early interaction between their proteins may be important
for downstream construction of the biofilm. Collectively
the data highlighted the importance of looking at multiple
genes at once opposed to single gene targets.
Conclusions
Overall, we have categorised isolates based on biological
properties relating to biofilm characteristics, and evalu-
ated these in models of infection and treatment, where
we have shown clear differences in virulence. In an
attempt to create a molecular basis of categorising these
strains we have used gene expression studies, and showed
that individual gene expression analysis of the biofilm re-
lated genes to differentiate and categorise biofilm-forming
isolates may be futile. Instead, we have shown that taking a
defined panel of genes during early biofilm growth may be
more informative. In particular, the panel of genes such as
SAP5, HWP1, EAP1, PLB1 and CDR1 investigated in tan-
dem could constitute an important step towards diagnostics
of C. albicans biofilm formation, though the use of tran-
scriptomics, such as RNA-Seq, may prove useful in identify-
ing novel diagnostic targets. Further work is required to
determine why some patients succumb to C. albicans
biofilms whereas others do not, as the HBF isolates do have
an increased pathogenic potential and are more difficult to
manage with antifungal agents.
Methods
Culture conditions and standardisation
Candida albicans SC5314, 3153A and a series of routine
patient anonymised clinical bloodstream isolates (n = 42)
collected under the approval of the NHS Scotland
Caldicott Gaurdians from the Royal Hospital for Sick
Children (Yorkhill Division), Glasgow, UK, as part of
candidaemia epidemiology surveillance study. All clinical
isolates obtained during this period were independently
identified using Colorex Candida chromogenic plates
(E&O Laboratories Ltd, Bonnybridge, UK) and were stored
in Microbank® vials (Pro-Lab Diagnostics, Cheshire, UK)at −80°C until further use. These isolates were sub-cultured
onto Sabouraud’s dextrose agar (SAB [Sigma-Aldrich,
Dorset, UK]). Plates were incubated at 30°C for 48 h
and maintained at 4°C. Isolates were propagated in
yeast peptone dextrose (YPD) medium (Sigma-Aldrich,
Dorset, UK), washed by centrifugation and resuspended in
the appropriate media (Sigma-Aldrich) to the desired con-
centration, as described previously [50].
Characterisation of Candida albicans biofilm formation by
clinical isolates
All C. albicans clinical isolates (n = 42) were standar-
dised to 1 × 106 cells/mL in RPMI-1640 and biofilms
grown in flat-bottomed 96 well microtitre plates at 37°C
for 24 h and biomass of each isolate assessed using the
crystal violet (cv) assay as previously reported [17], and
isolates were grouped based on their level of biomass
distribution (OD570nm values). Isolates that fell below the
1st quartile (Q1) were classed as having low biofilm for-
mation (LBF), strains with a biomass greater than the 3rd
quartile (Q3) were deemed isolates with high biofilm
formation (HBF), and those that lay in between were
classified as intermediate biofilm formation (IBF Q2). C.
albicans biomass was further assessed using dry weight
measurements. Selected isolates with LBF and HBF were
grown as biofilms in 12 well tissue culture plates for
24 h, as previously described, and the resulting biomass
homogenised in 1 mL of PBS using a cell scraper (STAR-
LAB, Milton Keynes, UK). This was then passed through
a 0.22 μm filter disc (Satorius Stedim) using a vacuum
and filters were dried at 40°C overnight before measur-
ing each isolates dry weight. Uninoculated controls were
used for background correction.
Biofilm visualisation
Representative isolates were also grown within 12 well
flat-bottomed tissue culture plates (Corning Incorpo-
rated, NY, USA) for 24 h before carefully washing with
PBS, stained with cv and then digitally imaged (Canon
IXUS 220 HS). For scanning electron microscopy (SEM)
representative C. albicans clinical isolates defined as LBF
and HBF were grown directly onto Thermanox™ cover-
slips (Nunc, Roskilde, Denmark), then processed and
analysed as previously described [51].
Cellular surface hydrophobicity assay
The cell surface hydrophobicity (CSH) was determined for
selected C. albicans clinical isolates with LBF (n = 10) and
HBF (n = 10). CSH was assessed using the microbial adhe-
sion to hydrocarbon test, with a few modifications [52,53].
Isolates were standardised to 1 × 106 cells/mL in RPMI-
1640 and grown as biofilms for 4 and 24 h in 75 cm2 flasks
(Nunc, Rochester, NY) at 37°C. These were then washed
with PBS and the resultant biomass scraped off and
Table 3 Candida albicans primers for real time qPCR
Gene Sequence (5' - 3')
ALS1 F - TTCTCATGAATCAGCATCCACAA
R - CAGAATTTTCACCCATACTTGGTTTC
ALS3 F - CAACTTGGGTTATTGAAACAAAAACA
R - AGAAACAGAAACCCAAGAACAACCT
ALS5 F - CTGCCGGTTATCGTCCATTTA
R - ATTGATACTGGTTATTATCTGAGGGAGAAA
EAP1 F - ACCACCACCGGGTATACAAA
R - GCCATCACATTTGGTGACAG
HWP1 F - GCTCAACTTATTGCTATCGCTTATTACA
R - GACCGTCTACCTGTGGGACAGT
BCR1 F - ATTGCCACCAATACCTGCTC
R - GGCTGTCCATGTTGTTGTTG
CPH1 F - ACGCAGCCACAAGCTCTACT
R - GTTGTGTGTGGAGGTTGCAC
EFG1 F - CCAGTGGTGGCAGTAATGTG
R - CAGTGGCAGCCTTGGTATTT
TUP1 F - GCTTCAGGTAACCCATTGTTGAT
R - CTTCGGTTCCCTTTGAGTTTAGG
OCH1 F - TCATCCAATGTTGCGTGAAT
R - TCATGATATCGCCACCTTCA
PMR1 F - GAATCCCCGCAGACATTAGA
R - GGGCCTGTTTTCACCAGTTA
MNN4 F - TGAGCAATCGTCAAAACCAG
R - GGCGGTTGTCATTTGTTGAT
MNT2 F - CGTCAAGGTGCCTGAAGAAT
R - GAGGAGGAGGAGGATTTTGG
CDR1 F - GTACTATCCATCAACCATCAGCACTT
R - GCCGTTCTTCCACCTTTTTGTA
MDR1 F - TCAGTCCGATGTCAGAAAATGC
R - GCAGTGGGAATTTGTAGTATGACAA
ZAP1 F - CGACTACAAACCACCAGCTTCATC
R - CCCCTGTTGCTCATGTTTTGTT
ACT1 F - AAGAATTGATTTGGCTGGTAGAGA
R - TGGCAGAAGATTGAGAAGAAGTTT
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1.0) and cells transferred into a glass tube and overlaid with
1/5th volume of xylene. Contents were vortexed for 1 min
and phases separated over 30 min. The aqueous phase was
carefully removed and OD590nm measured. The percentage
of hydrophobicity was calculated as ([OD590nm before
xylene overlay - OD590nm after xylene overlay]/ OD590nm
before xylene overlay) × 100%.
Antifungal susceptibility testing of biofilms
Antifungal testing to determine minimum inhibitory
concentration (MIC) of sessile cells was performed using
voriconazole (VRZ) and amphotericin B (AMB) (Sigma-
Aldrich, Gillingham, UK) on 24 h preformed biofilms, as
previously described in flat-bottomed, 96 well microtitre
plates [50]. C. albicans LBF (n = 10) and HBF (n = 10)
were tested in duplicate, on three separate occasions.
Sessile minimum inhibitory concentrations (SMICs) were
determined at 80% inhibition using an XTT (2,3-bis(2-
methoxy-4-nitro-5-sulfo-phenyl)-2H-tetrazolium-5-caboxa-
nilide) metabolic reduction assay [11].
Galleria mellonella pathogenicity assay
The pathogenicity of C. albicans isolates pre-defined as
LBF (n = 3) and HBF (n = 3) were assessed using the G.
mellonella killing assay, as described previously [54].
This biological model has been shown previously to be
useful in the study of fungal virulence [32,55,56]. Sixth-
instar G. mellonella larvae (Livefoods Direct Ltd, UK)
were stored in the dark and used within 7 days of ship-
ment. Ten random larvae with a bodyweight of between
200 to 300 mg were used for each group. Overnight
YPD cultures of each isolate were washed and standar-
dised to 1 × 107 cells/mL in PBS. Larvae were inoculated
using a 50-μl Hamilton syringe with 26 g needle by
injecting 10 μL aliquots (1 × 105 cells/larva) into the
haemocoel, through the hindmost proleg. In addition,
mock inoculated larvae pierced on the proleg with a
sterile needle and a PBS inoculated control group were
also included in each experiment. The infected larvae
were placed in sterile petri dishes, incubated at 37°C and
the number of dead larvae were scored daily. Larva was
considered dead when it displayed no movement in re-
sponse to touch together with a dark discolouration of
the cuticle. Pathogenicity of LBF and HBF was assessed
using a Kaplan-Meier plot with percentage survival moni-
tored over 7 days.
Histology analysis of infected Galleria mellonella
The morphology of the larvae infected with two isolates of
C. albicans LBF and HBF was examined. Larvae were in-
fected with the respective strains as described previously,
and after post-infection (24, 48 and 72 h) larvae were fixed
by a direct injection of formalin into the haemocoel and byformalin immersion at room temperature for 24 h. Paraffin
embedded samples were then transversally sectioned into
four-micron thickness using a microtome (microm HM
3335H, Thermoscientific). Sections were then stained with
Periodic Acid-Schiff (PAS) to evaluate C. albicans infected
cells. Whole larvae sections were examined for character-
isation and localisation of nodules by light optical micro-
scope visualisation (Leica microscope, model 020–519.502).
Two larvae were processed for each isolate, carried out on
three separate occasions.
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C. albicans clinical isolates exhibiting LBF (n = 10) and
HBF (n = 10) were selected for the analysis of genes re-
lated to biofilm formation [57]. Biofilms were grown in
24 well flat-bottomed plates for 4 and 24 h at 37°C, as
described above. Following incubation, biofilms were
washed with PBS, removed and homogenised using a
bead beater, and RNA extracted using the TRIzol™ (Life
Technologies, Paisley, UK) method as described previ-
ously by our group [42]. Total RNA was DNase (Qiagen,
Crawley, UK) treated and purified using an RNeasy
MinElute clean up kit (Qiagen, Crawley, UK), as per
manufacturer’s instructions. RNA was quantified and
quality assessed using a NanoDrop spectrophotometer
(ND-1000, ThermoScientific, Loughborough, UK). Next,
cDNA was synthesised from 200 ng of total RNA using
High Capacity RNA to cDNA kit (Life Technologies,
Paisley, UK) in a MyCycler PCR machine (Bio-Rad
Laboratories, Hertfordshire, UK), following manufac-
turers instructions.
All primers utilised for this study for quantitative PCR
(qPCR) were designed from their sequences obtained
from the Candida Genome Database (CGD) website
(http://www.candidagenome.org). The web-based primer
design software program Primer3 (http://primer3.ut.ee/)
was used. Primers were checked for specificity to C.
albicans using the NIH-BLAST for short or exact nu-
cleotide sequences (http://blast.ncbi.nlm.nih.gov/Blast.cgi).
PCR amplification efficiencies of all designed primer sets
were optimised prior to gene expression analysis, with effi-
ciencies of 90-110% used in this study. Details of the oligo-
nucleotides primers (Eurogentec, Southampton, UK) used
in this study are listed in Table 3. 200 ng cDNA was used
in a mastermix containing SYBR® GreenER™ (Life Tech-
nologies, Paisley, UK), UV-treated RNase-free water and
forward/reverse primers (10 μM), following manufac-
turers’ instructions. Cycle conditions consisted of 2 min at
50°C, 10 min at 95°C and forty cycles of 15 s at 95°C and
60 s at 60°C. Each parameter (LBF n = 10, HBF n = 10 at 4
and 24 h) was analysed in duplicate using MxProP Quanti-
tative PCR machine and MxProP 3000 software (Strata-
gene, Amsterdam, Netherlands) and controls consisted of
reactions in which reverse transcriptase template were ab-
sent. Gene expression was calculated using the ΔCt method
where the genes of interest were normalised to the house-
keeping gene Act1.
Clustering and heat map analysis
Differential expression of the selected genes from all iso-
lates with LBF (n = 10) and HBF (n = 10) were assessed
by clustering and heat map analysis using GenEx soft-
ware (Exiqon, Vedbaek, Denmark). In brief, percentage
expression data was pre-processed for log transform-
ation and mean values calculated (n = 10 for both LBFand HBF) for each gene before heat map production.
Each coloured cell in the heat map represents the vari-
able expression of genes in LBF and HBF at 4 and 24 h
time points. An increase in gene expression is repre-
sented by red and a down-regulation by green. Cluster-
ing techniques were used to show genes with similar
expression patterns (co-regulated genes) in each set of
isolates. The clustering was performed independently by
average linkage and Euclidean distances used as a dis-
tance measure for both dimensions in the data.
Statistical analysis
Graph production, data distribution and statistical analysis
were performed using GraphPad Prism (version 4; La Jolla,
CA, USA). After assessing whether data conformed to a
normal distribution data were transformed where necessary
and One Way Analysis of Variance (ANOVA) was used to
investigate significant differences between independent
groups. A Bonferroni post-test was used to determine
statistically significant differences between groups. The G.
mellonella survival curve was analysed using log rank test.
Student t-tests were used to measure statistical differences
between the two independent groups assessed in gene
expression studies. Statistical significance was achieved if
p < 0.05. IBM SPSS® (version 20) statistical analysis software
was used for correlation analysis. Two-tailed Spearman rho
correlation coefficient was determined separately for all 4
and 24 h selected genes expression versus 24 h biomass
data. Genes that had a significant correlation with biomass
were tested for correlations with the other genes as de-
scribed above.
Additional files
Additional file 1: Figure S1. Optimisation of C. albicans biofilms.
Standardised C. albicans SC5314 and 3153A (1×106 cells/mL) were grown
in flat-bottomed 96 well microtitre plates at 37°C for 24, 48 and 72 h in
RPMI-1640, YPD + 10% FCS, YNB + 100mM glucose and Spider media.
Negative controls were also included. Mature biofilms were carefully
washed with PBS, air-dried and biomass quantified by staining each
biofilm with 0.05% w/v crystal violet solution. The biofilms were washed
and 100% ethanol applied to destain each biofilm. The biomass was
quantified spectrophotometrically by reading absorbance at 570nm in a
microtitre plate reader (FluoStar Omega, BMG Labtech). Three replicates
for each isolate were used and carried out on two separate occasions.
Data represents mean ± SEM. Significant differences were observed
when comparing RPMI-1640 to all other growth media at 24 h (§§p<0.005,
§§§p<0.0001), 48 h (#p<0.005, ###p<0.0001) and 72 h (†p<0.05, †††p<0.0001).
Significant differences were also found between periods of biofilm develop-
ment within each growth media (*p<0.05, **p<0.01).
Additional file 2: Table S1. Percentage gene expression in C. albicans
4 and 24 h biofilms.
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